Understanding LCE1A: A Potential Drug Target and Biomarker (G353131)

Target Name: LCE1A

NCBI ID: G353131

LCE1A

Understanding LCE1A: A Potential Drug Target and Biomarker

LCE1A (LCE1A_HUMAN) is a protein that is expressed in various tissues of the human body, including the brain, heart, liver, and muscle. It is a member of the LCE1A family, which includes several similar proteins that are involved in various cellular processes, including cell signaling, DNA replication, and chromatin remodeling.

One of the unique features of LCE1A is its ability to interact with other proteins, both within its own family and outside of it. This interaction with other proteins has led to its potential as a drug target or biomarker.

Recent studies have shown that LCE1A is involved in several different cellular processes, including cell signaling, angiogenesis (the formation of new blood vessels), and fibrosis (the progression of tissue damage). It is also involved in the regulation of cell apoptosis (programmed cell death), which is a natural response to harmful stimuli that helps the body eliminate damaged or dysfunctional cells.

In addition to its role in cellular processes, LCE1A is also a potential biomarker for several diseases, including cancer, cardiovascular disease, and neurodegenerative disorders. Its involvement in these diseases has led to its potential as a drug target or diagnostic marker.

One of the main challenges in studying LCE1A is its complex structure and the interactions it has with other proteins. To gain a better understanding of its functions, researchers have used a variety of techniques to study its behavior, including biochemical assays, gene editing, and cell-based assays.

One of the most promising areas of research surrounding LCE1A is its potential as a drug target. LCE1A has been shown to interact with several protein kinases, including Src,FAK, and PDGFR. These proteins are involved in various cellular processes, including cell signaling, angiogenesis, and fibrosis. By targeting these proteins, researchers may be able to develop new treatments for diseases that are currently untreated or have limited treatment options.

In addition to its potential as a drug target, LCE1A is also a potential biomarker for several diseases. Its involvement in the regulation of cell apoptosis makes it a potential marker for cancer and neurodegenerative disorders. Additionally, its involvement in cell signaling and angiogenesis makes it a potential marker for cardiovascular disease.

Overall, LCE1A is a protein that has the potential to be a drug target or biomarker for several diseases. Its complex structure and interactions with other proteins make it a challenging target, but its involvement in cellular processes makes it a promising area of research. Further studies are needed to fully understand its functions and potential as a drug or biomarker.

Protein Name: Late Cornified Envelope 1A

Functions: Precursors of the cornified envelope of the stratum corneum

The "LCE1A Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about LCE1A comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets